APR 7 2000

APR 10 2000

Attorney Docket No.: BIV-014.01

TECH CAPTURED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ningning Miao

Serial No.: 08/900,220

Filing Date: July 24, 1997

For: Method of Treating Dopaminergic and GABA-nergic Disorders

Attorney Docket No.: BIV-014.01

TECH CAPTURED STATES PATENT AND TRADEMARK OFFICE

POX SEQ WITH ACCURATION SEC WITH ACCURATION SEQ WITH ACCURATION SEQ WITH ACCURATION SEC WITH ACCURATION SEQ WITH ACCURATION SEC WITH ACCURATI

## **CERTIFICATE OF MAILING**

I hereby certify that the foregoing document is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on this 13th day of April 4, 2000.

Jonathan Furtado

## RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES

Applicants submit herewith a revised sequence listing which is fully compliant with the requirements of 37 CFR 1.821 through 1.825, in response to the Office Action mailed March 7, 2000. We submit herewith a hard copy of the sequence listing and a computer readable form of the sequence listing (the diskette) as requested.

Additionally, I hereby state that the content of the Sequence Listing and the computer-readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

I further state that this submission, filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter.

We believe that we have appropriately provided for fees due in connection with this submission, however, if there are any other fees due in connection with the filing of this Response, please charge the fees to our **Deposit Account No. 06-1448**.

If there are any questions after review of this paper, the Examiner can contact the undersigned as (617) 832-1754.

> Respectfully submitted, FOLEY, HOAG, & ELIOT

David P. Halstead Reg. No. 44,735

April 4, 2000

Patent Group Foley, Hoag & Eliot LLP One Post Office Square Boston, MA 02109-2170 Tel: (617) 832-1000

FAX: (617) 832-7000

TOTICE TO COMPLY WITH EQUIREMENTS FOR PATENT APPLICATIONS CONTAINING TUCLEOTIDE SEQUENCE AND DR AMINO ACID SEQUENCE DISCOURES
he nucleotide and/or amino acid sequence disclosure contained in this application does ot comply with the requirements for such a disclosure as set forth in 37 CFR 1.821825 for the following reason(s):  APR 10 2000 N
¬
1. This application clearly fails to comply with the requirements of 37 CFR 1.821
1.825. Applicant's attention is directed to the regulations, published at 1114 OG 29 ay 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on
aper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been
ubmitted as required by 37 CFR 1.821(e).
t a serve of the Mossesses Vietical is computed usedable form bag been gubmitted
4. A copy of the "Sequence Listing" in computer readable form has been submitted.
conver, the content of the computer readable form does not comply with the requirements f 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw equence Listing."
<del></del>
5. The computer readable form that has been filed with this application has been
ound to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem eport. A substitute computer readable form must be submitted as required by 37 CFR .825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer eadable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7.
ther:
pplicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence
isting"
An initial or gubstitute paper copy of the "Sequence Listing", as well as an
, amendment directing its entry into the specification
√1
A statement that the content of the paper and computer readable copies are the same
and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
or questions regarding compliance with these requirements, please contact
for Rules Interpretation, call (703) 308-1123 for CRF submission help, call (703) 308-4212

Please return a copy of this notice with your response.